Huntington's disease (HD) is caused by a mutation in the Huntingtin (HTT) protein. We previously reported that the 23aa peptide of HTT protein, P42, is preventing HD pathological phenotypes, such as aggregation, reduction of motor performances and neurodegeneration. A systemic treatment with P42 during the pre-symptomatic phase of the disease showed therapeutic potential in R6/2 mice. We here tested P42 effects when administered during the post-symptomatic phase. The P42 treatment alleviated deficits in motor performances, even when symptoms have already started. Because changes in the level and activity of brain-derived neurotrophic factor (BDNF) have been shown to play a central role in HD, we analysed the influence of P42 on BDNF deficit and associated phenotypes. Our data suggest that P42 is involved in the spatiotemporal control of bdnf and trkB mRNA and their protein levels. Related to this enhancement of BDNF-TrkB signalling, R6/2 mice treated with P42, exhibit reduced anxiety, better learning and memory performances, and better long-term potentiation (LTP) response. Finally we identified a direct influence of P42 peptide on neuronal plasticity and activity. These results suggest that P42 offers an efficient therapeutic potential not only by preventing aggregation of mutant HTT at early stages of the disease, but also by favouring some physiological functions of normal HTT, as P42 is naturally part of it, at the different stages of the disease. This makes P42 peptide potentially suitable not only to prevent, but also to treat HD.
Introduction
Huntington's disease (HD) is a rare neurodegenerative disease, with a prevalence varying between regions across the world, with the highest rate among the Caucasians with 1.3-1.7 per 10 000 (1-3). It is a genetic disease that results from abnormal expansion of a polyQ domain in the Huntingtin (HTT) protein.
When this domain contains more than 35 Glutamines (Q), the polyQ-HTT protein is mutant. The HTT protein is quite large (3144 aa) and is normally cleaved (4) . N-terminus fragments with expanded polyQ, derived either from protein cleavage or from the use of alternative splicing site on the mRNA, are highly toxic (5) (6) (7) . When accumulating, these mutant polyQ-HTT fragments form aggregates, and drive neurodegeneration primarily affecting the striatum but also other brain areas at late stages of the disease, leading to a loss of the brain volume and an enlargement of ventricles (8) . Severe motor, but also cognitive and psychiatric symptoms are also associated with the disease (9, 10) . Loss of brain-derived neurotrophic factor (BDNF) was found to play an important role in motor but also in cognitive and neuropsychiatric defects in HD, and to contribute to striatal neurodegeneration (11) . A decrease of both bdnf mRNA and protein is detected in cerebral cortex from HD patients (12) and in R6/2 mouse model of HD (13) . The level of expression and the transport of the BDNF were identified to be key contributors of striatal neurodegeneration and HD pathogenesis (14) . Notably, HTT enhances BDNF vesicular transport along microtubules (15) . Although BDNF has emerged as a key regulator in the selective vulnerability of striatal neurons in HD, its activity also requires the modulation of its receptor, Tropomyosin-related kinase B (TrkB) (16) . In particular an increase in dendritic trafficking of trkB mRNA and its local translation could contribute to a rapid response to BDNF (17) .
The identification of a curative treatment against this disease is still actively sought. HD is an autosomal dominant disease, and the only presence of one mutated allele is sufficient for the occurrence of the symptoms. Associated to that, it has been observed that the ratio between normal HTT and mutant polyQ-HTT is crucial in the onset and progression of the disease (15, (18) (19) (20) (21) (22) (23) (24) . We indeed found that polyQ-HTT aggregation in HeLa cells is prevented in the presence of around 600aa N-terminal part of normal HTT from Human or Drosophila (23) . This led to identify, within normal human HTT, a 23aa peptidic domain (P42), sharing homologies with Drosophila that prevents aggregation process in HeLa cells. In vivo, we found that P42 was protective of different phenotypes induced by the expression of the polyQ-HTT in Drosophila (25) , but also in R6/2 mouse model of HD (26) . Transgenic R6/2 mice express the first exon1 of mutant human HTT in presence of around 120 CAG repeats corresponding to a very severe model of HD (10) . However this model recapitulates many of the clinical features of HD, including lower motor performances with enhanced involuntary reflex movements, body weight loss, reduction of brain volume and decreased BDNF signalling associated with a loss of memory and enhanced anxiety, corresponding to a panel of HD symptoms in humans (17, 27, 28) . Therefore, this model is particularly suitable to test treatments, since the first symptoms of R6/2 mice start at around week 6, leading to their death when 14 weeks old (9) .
Therapeutic peptides present advantages, as being potentially not toxic, but also some inconveniences. Indeed most of them do not cross the blood-brain barrier and when entering cells they are rapidly degraded. To overcome these problems, we previously tested an original strategy for P42 delivery, where P42TAT fusion peptide was dissolved in the aqueous phase of water-in-oil microemulsions (Aonys V R technology developed by Medesis pharma, Baillargues, France). This P42TAT-Aonys V R treatment (referred as P42T treatment) allows non-invasive buccal/rectal mucosal repetitive administrations of the peptide. Such treatment with P42T in R6/2 mice has already been tested from week 2 before onset of symptoms, confirming the potential use of P42T as a preventive treatment of HD (26) .
In order to determine whether P42T could also be used to treat HD symptoms, we tested its actions when applied postsymptomatically, from week 7. In this report, we analysed the phenotypical consequences of a post-symptomatic P42T treatment of R6/2 mice, compared with a pre-symptomatic treatment, and showed that the late action of P42T may occur though an enhancement of the BDNF-TrkB signalling. Finally, we also identified a direct effect of P42T on synaptic plasticity and neuronal activity.
Results
In this report, mice cohorts were treated either with P42TAT fusion peptide formulated in Aonys V R water-in-oil microemulsions (P42T) or empty ones used as placebo control (NT). The question we asked was whether a treatment with P42T could be used to treat HD symptoms at later stages of the disease, once the symptoms have already appeared (9) , starting the treatment at week 7 (Fig. 1A ).
Post-symptomatic treatment with P42T
HD is characterized by a neostriatal volume loss first detected in 6-week-old R6/2 mice (11). This leads to a significant enlargement of the ventricles in 12-week-old placebo R6/2 mice (treated with empty microemulsions) (NT), compared with wild-type (Wt) mice (Fig. 1B , see Supplementary Material, Fig. S1 for genotyping). P42T treatment provided at late stages of the disease was significantly reducing brain atrophy, suggesting a slowdown of the neuronal degeneration of the striatum. This confirms that P42T treatment is able not only to prevent neuronal defects (26) , but also may be useful to treat neurodegeneration induced in the context of the disease.
Other prominent phenotypic changes in R6/2 mice are deficits in their motor performances (10), which we assessed using the rotarod test. At week 7 when the post-symptomatic treatment starts, R6/2 mice all presented significant lower motor performances than Wt mice, without significant differences in R6/2 groups that will be treated or not with P42T from week 7 (ns) (Fig. 1C) . On the contrary, we observed that, after the treatment started, P42T-treated R6/2 mice exhibited significantly improved performances over time with respect to placebo R6/2 mice (NT), as evaluated by two-way ANOVA (*P < 0.05; Fig. 1C ). For instance, at week 8 and week 9, P42T-treated R6/2 mice exhibited 18% better performances compared with untreated R6/2 mice (Fig. 1C) .
These data showed that the P42T post-symptomatic treatment improved motor symptoms in R6/2 HD mice.
P42 peptide was previously shown to prevent aggregation process in different models of HD (25) , including R6/2 mice when provided during the pre-symptomatic phase, where the number (but not the size) of aggregates was found to be significantly reduced by 50% (26) .
Here we monitored the number and the size of the aggregates present in R6/2 mice treated with P42T starting later at week 7. After quantification on brain sections, we found that, unlike after P42T pre-symptomatic treatment, the number and size of these nuclear inclusions were not significantly reduced by post-symptomatic P42T treatment (Fig. 1D) .
This indicates that although P42T prevented the formation of aggregates (2, 25, 26) , it failed to destruct them once they are formed.
Therefore, we suspected that the late effects of P42T on the neuronal fate that we observed might involve other modes of action than its previously identified role on aggregation process.
Relationships between P42T and BDNF signalling
Because BDNF plays a central role in HD, we analysed the influence of P42T on BDNF content. A reduction of the bdnf expression level in the cortex depletes BDNF in the striatum and leads to severe motor deficits. HTT protein was found to play a crucial role in both the production and the transport of BDNF (15, 29) , processes that are disrupted in HD. P42 being a part of the HTT protein (25), we asked whether P42T could interfere with BDNF alteration noticed in HD, which might explain an action of P42T, during all the phases of the disease, pre-symptomatic (starting size: brain sections of Wt NT, and R6/2 NT or R6/2 P42T were stained with DAPI. Slices corresponding to À0.6 or À0.8 mm Bregma point were selected with the slide scanner Nanozoomer Hamatsu and the size of the ventricles measured. Ventricle size varies in the different conditions. Using Mann-Whitney test: Wt NT (0.058 6 0.007, n ¼ 14) versus R6/2 NT (0.263 6 0.041, n ¼ 10); ***P < 0.001; R6/2 NT (0.263 6 0.041, n ¼ 10) versus R6/2 P42T (0.170 6 0.025, n ¼ 18); *P < 0.05; Wt (0.058 6 0.007, n ¼ 14) versus R6/2 P42T (0.170 6 0.025, n ¼ 18); ***P < 0.001. A significant recovery exists but the recovery is not complete. (C) Rotarod test: motor performances were at week 2) or post-symptomatic (starting at week 7), independently of its action on aggregation process. Therefore we compared the effects of shorter and more immediate treatment (post-symptomatic: 'short-term') and longer (pre-symptomatic: 'long-term') treatment with P42T on BDNF levels of expression (mRNA quantified by RT-qPCR and proteins quantified relative to total proteins, using Stain-Free TM method and western blots, see Supplementary Material, Fig. S2 ). Analyses were carried out in the cortex and in the striatum (Fig. 2 ) that have been separately dissected. We first confirmed that BDNF levels of expression in the cortex (both mRNA and proteins) were significantly reduced in R6/2 mice compared with Wt mice treated with empty microemulsions ( Fig. 2A) . We also observed that when P42T treatment started during the pre-symptomatic phase of the disease, P42T-treated R6/2 mice presented slightly higher level of expression of bdnf mRNA in the cortex (0.05 < P < 0.1; Fig. 2A ). This suggested that P42T has the ability to interfere on bdnf transcriptional level that is affected in HD.
We further tried to better identify the action of P42T on BDNF signalling.
Most of the phenotypes affected in HD result from the BDNF signalling, mediated by the TrkB receptor (30) . A reduction of the trkB mRNA level of expression has been noticed in HD mouse models, and the effectiveness of BDNF was shown to depend on the proper expression of TrkB (16) .
Therefore we decided to analyse the action of P42T on the level of expression of both the bdnf and its receptor trkB in the cortex when providing the peptide during the pre-symptomatic or the post-symptomatic phases of the disease (Fig. 2) .
We first confirmed that, like for bdnf, the level of expression of trkB mRNA was significantly reduced in the cortex (Fig. 2B ) of R6/2 mice.
We also found that whereas a longer pre-symptomatic treatment with P42T drives an enhancement of both bdnf and trkB mRNA expressions in the cortex ( Fig. 2A and B) , a short-term post-symptomatic treatment only leads to an improvement of trkB in the cortex (Fig. 2B ), suggesting that P42T seems to primarily act on trkB, therefore ensuring an enhancement of the BDNF signalling activity in the cortex. Protein levels of TrkB were however not reduced in R6/2 cortex ( Fig. 2B and C) , as observed previously (16) . Globally the effects of P42T on both the bdnf and trkB in the cortex were only detectable at the transcriptional level.
In the striatum (Fig. 2D-F ) which is particularly vulnerable to BDNF signalling deficit (16), we found that P42T significantly enhances the bdnf transcriptional level when mice undergo a long-term pre-symptomatic treatment, without modifying BDNF protein levels (Fig. 2D) . Note that in the striatum BDNF proteins essentially correspond to the mature forms (compare Fig. 2F with 2C) . Notably, we have identified that P42T acts primarily at the level of the TrkB protein ( Fig. 2E and F) , with both long-term and short-term P42T treatments. This significant increase in TrkB protein could ensure a rapid activation of the BDNF signalling in the striatum.
To summarize, in the cortex and in the striatum, only P42T long-term pre-symptomatic treatment increases bdnf mRNA ( Fig. 2A and D) , whereas P42T treatments (pre-and post-) increase trkB mRNA in the cortex (Fig. 2B) , and TrkB protein in the striatum ( Fig. 2E and F) .
These data show that treatment with P42T improves spatiotemporally the expressions of bdnf and trkB, which would optimize the signalling by BDNF.
Effect of P42T on anxiety and memory in R6/2 mice These defects of the BDNF signalling pathway in the pathogenesis of HD play a pivotal role, and contribute to synaptic dysfunction and synaptic plasticity deficits, which impacts the cognitive decline and motor deficits observed in HD (11) . Since P42T enhances the expression levels of bdnf and trkB, we tested other defects impaired in HD that are related to a reduction in BDNF signalling.
Associated to severe motor impairments, psychiatric and cognitive problems are present in HD. At the behavioural level, HD pathogenesis drives problems in learning and memory and enhances anxiety, which even precede the onset of motor deficits (31) . BDNF-TrkB signalling deficit is required in the learning and memory impairment in HD (32) . We therefore tested the effect of P42T treatment on these different behavioural responses.
The light/dark transition test is one of the most widely used test to measure anxiety-like behaviour in mice. The test is based on the natural aversion of mice to brightly illuminated areas and on their spontaneous exploratory behaviour in novel environment. The apparatus consists of a dark chamber and a brightly illuminated chamber. Mice are allowed to move freely between the two chambers. Wt mice spend half of their time in the light box (Fig. 3A) . R6/2 mice rather avoid the light box, spending around 35% of their time in the bright compartment (*P < 0.05). The effect of P42T on anxiety response in R6/2 mice appeared limited, with statistic tests that did not reach significance. However, we observed that, for both the presymptomatic and post-symptomatic treatments, P42T alleviated this trend since P42T-treated R6/2 mice behaved like Wt mice, with non-significant differences (Fig. 3A) . This shows that R6/2 mice tend to be less anxious under treatment with P42T.
To confirm this result, we also used an open-field response. Indeed, during the habituation phase (S1), in absence of any object, we analysed the time spent in the central area of the arena. Whereas increased anxiety results in preference for the edges of the arena, decreased anxiety leads to longer exploration of the central part. As expected, R6/2 mice were significantly more anxious than Wt mice, by spending less than half the time in the central part compared with Wt. R6/2 mice treated, pre-or post-symptomatically, with P42T, behave like Wt mice and spend twice more time to explore the central arena (Fig. 3B) . This corroborates the trends observed in the light/dark box test, and confirms the benefit of treatment with P42T on anxiety.
Impaired learning that occurs before or concurrent with motor dysfunction or neuron loss has been described in HD mouse models. The memory was assessed by using object recognition task. In the squared arena in presence of two objects (similar in session S2, and one novel in session S3), we analysed the Analysis of BDNF and TrkB levels of expression. mRNA and protein levels were measured from dissected cortex (A-C) and striatum (D-F) of Wt and R6/2 mice treated with P42 (P42T) or not (NT). Treatments were pre-symptomatic (Pre) or post-symptomatic (Post). RT-qPCR were performed on mRNA extracted from dissected tissues. All samples were normalized to ß-actin reference, and quantifications were performed on triplicates and are expressed as fold change versus Wt mice (100%). Protein levels from the same animals were analysed by western blots. Three major forms of the BDNF are detected: 48 kDa corresponding to the pro-BDNF, 14 kDa corresponding to the mature BDNF and 25KDa corresponding to the dimeric form (65) . Quantifications were performed on all the three forms. number of visits for both objects and define the ratio (%) between the number of visits for object at position 2 over the total number of visits, providing a recognition index (Fig. 3C ). During the training session (S2), Wt or R6/2 mice treated or not with P42T pre-or post-symptomatically, showed a similar exploration of both identical objects whatever their position (Fig. 3C) .
During the memory session (S3), untreated Wt, but not R6/2 mice, showed a significant preferential exploration of novel object at position 2 ( # P < 0.05 versus theoretical level 50%; Fig. 3C ).
The P42T treatments restored a preferential exploration of the novel object, indicating that the peptide treatment significantly improved recognition memory. Note that pre-symptomatic or post-symptomatic treatments both induced similar effects, with a recognition index greater than 50%. We therefore observed that P42T-treated R6/2 mice recovered memory alterations, a behavioural consequence coherent with the effect of P42T on bdnf levels.
P42T treatment restores LTP in hippocampal slices prepared from R6/2 mice Abnormalities in BDNF expression and trafficking detected in HD lead to synaptic dysfunction and synaptic plasticity deficits (33, 34) , which could account at least in part for the HD symptoms. R6/2 mice indeed present deficits in hippocampal longterm potentiation (LTP), a form of synaptic plasticity widely regarded as a neurobiological substrate for memory (35) . Because bdnf mRNA levels are substantially reduced in R6/2 mice and since up-regulating endogenous BDNF was shown to restore LTP in HD mice (34), we tested whether P42T that is enhancing the BDNF-TrkB signalling pathway, would reverse LTP deficits in the mutant mice.
For this, LTP was triggered by applying brief high-frequency stimulation (100 Hz, 1 s), in the CA1 area of the hippocampus of R6/2 mice treated or not with P42T (pre-symptomatic treatment), and of age-matched Wt mice as control (Fig. 4) . Wt animals show a robust and stable LTP of fEPSP expressed as a percentage of baseline level ( Fig. 4A and B in white). In slices from R6/2 mice, this level was significantly decreased to percentage of basal level ( Fig. 4A and B in black, see representative fEPSP traces in Fig. 4C ). However, in slices from R6/2 mice treated with P42T, LTP level percentage was recovered ( Fig. 4A and B in grey) to a normal percentage, not significantly different from the level obtained in control Wt animals (Fig. 4B ).
These findings confirm first that mutant HTT severely impairs the induction of LTP (Fig. 4A and B) and second that chronic treatment with P42T delays LTP loss observed in the hippocampus of R6/2 mutant mice.
We further tested whether infusing directly P42TAT peptide (100 nM solution) for 20 min would detectably change baseline transmission in mice brain slices. Acute application of P42TAT peptide (100 nM solution) for 20 min tends to stimulate potentiation on R6/2 mice slices (P < 0.1; Fig. 5A and C) . Notably, it induced an enduring and significant potentiation of the excitatory synaptic transmission in the CA1 area of the hippocampus of R6/2 mice that were previously treated with P42T (pre-symptomatic treatment) (*P < 0.05; Fig. 5B and C) . This shows that the prior exposure with P42T significantly amplifies the response (Fig. 5C ).
To confirm this direct effect of P42TAT peptide, we further infused hippocampal slices of Wt mice with three different concentrations of P42TAT peptide solutions (100 nM, 10 mM and 20 mM), and identified a dose-response effect (Fig. 6A) , with only a slight change of baseline transmission at 100 nM ( These results suggest that P42T is able to facilitate neuronal plasticity acutely, in hippocampal cells, in mutant, but also in Wt mice. Related to this, trkb mRNAs and proteins were found significantly enhanced in Wt hippocampal cells after P42T treatment (Supplementary Material, Fig. S3, ) .
Next, we addressed the presynaptic or the postsynaptic origin of changes in synaptic efficacy induced by P42TAT. To this end, we performed paired-pulse stimuli (S1 and S2 stimulations), which consisted of two close stimulating pulses of the same intensity and duration, but with a shorter interval of 50 ms (36,37), before and after the application of 10 mM P42TAT (Fig. 6B) .
If P42TAT is acting at the presynaptic site, we expect a change in the paired-pulse ratio (PPR: S2/S1) after P42TAT incubation. In contrast, we expect the PPR to remain stable for postsynaptic effect, particularly because of the postsynaptic receptor population that should not have time to change during paired-pulse stimulation.
By testing paired pulse before and after P42TAT application (with representative traces shown on Fig. 6B ), we found that the PPR remains unchanged (Fig. 6B) . While amplitudes of individual currents are enhanced by the treatment (Fig. 6B) Results correspond to triplicates for mRNA and duplicates for protein levels. Bars represent mean 6 SEM. *P <0.05; **P < 0.01; ***P < 0.001 with respect to Wt or R6/2 placebo. 3.6%, n ¼ 6); *P < 0.05. R6/2 (34.5 6 3.6%, n ¼ 6) versus R6/2 P42T (41.5 6 5.1%, n ¼ 6); P > 0.10 (ns). (B) Test in open-field: 11-week-old mice were freely exploring the chamber during 10 min. The % of time spent in the centre of the arena was measured. Using Mann-Whitney test: Pre-symptomatic treatment: Wt (14.1 6 2.9%, n ¼ 5) versus R6/2 (7.4 6 1.9%, n ¼ 7); *P < 0.05. R6/2 (7.4 6 1.9%, n ¼ 7) versus R6/2 P42T (15.8 6 2.3%, n ¼ 11); *P < 0.05. Post-symptomatic treatment: Wt (10.9 6 1.2%, n ¼ 6) versus R6/ 2 (5.6 6 0.4%, n ¼ 5); *P < 0.05. R6/2 (5.6 6 0.4%, n ¼ 5) versus R6/2 P42T (11.0 6 2.0%, n ¼ 5); **P < 0.01. (C) Measure of recognition memory using the object recognition test: 11-week-old mice were first allowed to freely explore the arena during 10 min (Session 1), and several parameters tested, among which is time spent in the centre of the arena (see in B). During the training phase (Session 2, S2), mice explored the same object in two positions. During the memory test (Session 3, S3) mice explored one familiar and one novel object in position 2. Recognition index (%) correspond to the number of visits for object at position 2 over the total number of visits and 50% is the score for mice with no memory. S2 pre-symptomatic: Wt (55.6 6 10.5%, n ¼ 5); R6/2 (41.5 6 5.2%, n ¼ 10); R6/2 P42T (43.7 6 7.7%, n ¼ 8). All P > 0.05 versus 50% level. S2 post-symptomatic: Wt (55.4 6 8.3, n ¼ 5); R6/2 (48.8 6 13.8%, n ¼ 5); R6/2 P42T (51.2 6 11.1%, n ¼ 5). All P > 0.05 versus 50% level. S3 pre-symptomatic: Wt (61.5 6 3.8, n ¼ 5, # P < 0.05 versus 50% level); R6/2 (48.9 6 6.9%, n ¼ 9, P > 0.05); R6/2 P42T (69.2 6 7.2%, n ¼ 7, # P < 0.05 versus 50% level). S3 post-symptomatic: Wt (64.0 6 3.4, n ¼ 5, # P < 0.05 versus 50% level); R6/2 (55.8 6 15.0%, n ¼ 6, P > 0.05); R6/2 P42T (81.4 6 10.6%, n ¼ 5, # P < 0.05).
ratio S2/S1 remain unchanged, indicating that P42TAT is not acting at the presynaptic side of the terminal, but rather at the postsynapse.
Effect of P42TAT on intracellular Ca 2þ concentration
BDNF was found to enhance calcium activity in developing hippocampal neurons, therefore influencing synapse formation and neuronal activity (38) . We wanted to test whether P42TAT may also have such an impact on synaptic connectivity and neuronal activity.
To this end, we tested the effect of addition of P42TAT peptide on intracellular Ca 2þ concentration ([Ca 2þ ]i) of cultured rat hippocampal neurons at 15DIV (Fig. 7) . The responsiveness of the neurons to glutamate was first tested by applying di-hydroxy-phenyl-glycine (DHPG), a potent agonist of group I metabotropic glutamate receptor, before and after the addition of the peptide. The effects of P42TAT or TAT peptides were analysed on these neurons under static conditions. [Ca 2þ ]i changes were measured by monitoring fura-2 fluorescence. Profiles of individual cells were analysed and characteristic profiles are provided on Figure 7A . In order to better quantify the effects of these peptides on [Ca 2þ ]i, we defined arbitrarily a threshold of F340/F380 fluorescence ratio. Indeed, in the presence of P42TAT, reversible changes in F340/F380 occurred either as monotonous increases or spikes (Fig. 7A) . Whereas neurons incubated with TAT alone do not exceed the threshold, as KREBS, we identified that in the presence of P42TAT, spikes appear above the threshold. Data accumulated on several cells (around 20) provided a clear picture of this enhancement of F340/F380 fluorescence ratio over basal threshold with P42TAT, but not TAT (Fig. 7B) . A quantification of the time spent by the F340/F380 fluorescence ratio above the basal threshold confirmed that P42 could increase [Ca 2þ ]i in cultured hippocampal neurons (Fig. 7C) . These data highlight an effect of P42 peptide on neuronal activity.
Discussion
P42 peptide is a domain of the HTT protein and was shown to be protective of phenotypes induced in a context of HD (25, 26) . Some of the protective properties of P42T treatment were previously identified in R6/2 mouse model of HD when providing the peptide in a pre-symptomatic phase of the disease (26) .
In this report we also tested the effect of P42T treatment in the post-symptomatic phase of R6/2 mice, starting at week 7. As suspected, we confirmed that the effect of P42T on aggregates is an early event, preventing their de novo formation (2, 26) . Therefore an important issue was to identify how P42T was able to perform late effects, even though the aggregates are already formed and persistent.
We found that even when provided at later stages, P42T prevents brain atrophy and significantly improves the motor performances of R6/2 mice over time.
Because P42 peptide belongs to the HTT protein, it might play important roles in different processes where the HTT protein is involved. HTT was for instance shown to interfere on BDNF pathway, a key contributor in HD (16, 39, 40) . It has been indeed reported that changes in endogenous BDNF levels contribute to striatal atrophy and to the severity of cognitive and motor symptoms in HD mice (11, 41) .
Hence we asked whether P42T could act on BDNF signalling pathway. Most of the BDNF protein found in the striatum is produced and transported from the cerebral cortex (42, 43) . The survival and the activity of the neurons of the striatum also depend on this BDNF source from the cortex (14,39) . Thus, it has For R6/2 NT brain slices, using Mann-Whitney test: before (104.2 6 3.09%, n ¼ 5) versus after (120.5 6 8.65%, n ¼ 5); P < 0.1. For R6/2 P42T brain slices, using MannWhitney test: before (100.8 6 1.35%, n ¼ 3) versus after (149.1 6 10.97%, n ¼ 3); *P < 0.05. P42TAT peptide application applied to R6/2 P42T or R6/2 NT mice. Using MannWhitney test: R6/2 NT (120.5 6 8.65%, n ¼ 5) versus R6/2 P42T (149.1 6 10.97%, n ¼ 3); *P < 0.05. Figure 6 . Dose-response effect of P42TAT peptide on synaptic transmission in the hippocampus of Wt mice. (A) Excitatory synaptic transmission was recorded in the CA1 area of Wt mice hippocampus by stimulating the Schaffer collaterals/commissural fibers pathway. fEPSPs were evoked under basal condition by stimulating at 0.066 Hz. P42TAT was applied at different concentrations: 100 nM in black (n ¼ 2), 10 mM in grey (n ¼ 6), 20 mM in white (n ¼ 3) for 20 min directly in the medium superfusing hippocampal slices. Representative (fEPSP) traces recorded during baseline (grey) and 60 min after P42TAT application (black) with different concentration as indicated. Quantification of the potentiation according to P42TAT peptidic concentration. P42TAT was tested at 100 nM (n ¼ 3), 10 mM (n ¼ 6) and 20 mM (n ¼ 3) on hippocampal slices from Wt mice. Graph corresponds to averaged fEPSP amplitudes normalized to basal transmission. Excitatory synaptic transmission in Wt mice was analysed 60 min after P42TAT stimulation at different concentrations. Using Mann-Whitney test: 100 nM (120.8 6 4.487%, n ¼ 3) versus 10 mM (163.9 6 12.7%, n ¼ 6); *P < 0.05, 100 nM (120.8 6 4.487%, n ¼ 3) versus 20 mM (229.0 6 13.70, n ¼ 3); **P < 0.01, 10 mM (163.9 6 12.7%, n ¼ 6) versus 20 mM (229.0 6 13.70, n ¼ 3); *P < 0.05. These data show a concentration-dependent effect of P42TAT peptide on excitatory synaptic transmission in Wt mice when acutely applied. (B) Paired-pulse facilitation analysis in the presence of P42TAT: paired pulses composed of two identical stimulations (S1: first stimulation S2: second stimulation, separated by a 50 ms interval) have been performed on hippocampal slices of six mice. The stimulations are provided either before or after P42TAT incubation (10 mM). Representative traces of the mean for the paired-pulse series are shown before application of P42TAT (in grey) and after application of P42TAT (in black). PPR (S2/S1) before (in grey) or after P42TAT application (in black). This graph shows that the facilitation induced by paired pulse is similar before and after the application of P42TAT. Using Wilcoxon matched pairs test: before P42TAT (1.652 6 0.03, n ¼ 6) versus after P42TAT (1.63 6 0.01, n ¼ 6); P > 0.1 (ns). 3021 | Human Molecular Genetics, 2018, Vol. 27, No. 17 been proposed that reduction in BDNF level in the cerebral cortex or in its delivery may contribute to striatal vulnerability in HD (15, 29) . A reduction of bdnf level of expression in the brain has been observed in transgenic mice and patients with HD, and Wt HTT stimulates bdnf gene transcription and protein production (29) . Actually the striatal vulnerability in HD also results from a deficit in trkB mRNA levels in both the cortex and the striatum (16) .
We verified that the levels of bdnf and trkB mRNA expressions are indeed affected in both the cortex and the striatum of R6/2 mice. We also observed a dynamic distribution of BDNF and TrkB after P42T stimulation.
Our data suggest that the primary effect of P42T (following a short-term post-symptomatic treatment) may occur on the level of expression of trkB mRNA in the cortex and of TrkB protein in the striatum, which might optimize the BDNF signal in the striatum. A long-term pre-symptomatic treatment is additionally enhancing the bdnf mRNA level in the cortex and the striatum, probably as a consequence of the TrkB enhancements. This shows that P42T seems to control the balance between bdnf and trkB cortico-striatal expressions, therefore modulating its action on neuronal activity in the striatum.
We further tested whether P42T is able to interfere with phenotypes associated to BDNF signalling defects. As previously mentioned, there is a clear link between BDNF defects and brain atrophy or motor dysfunctions in HD (11, 41) , defects that are clearly improved by P42T, with both pre- (26) , and postsymptomatic treatments, as shown in this report. BDNF signalling also plays a crucial role for psychiatric and cognitive deficits of HD (32) . We therefore studied the putative role of P42T on anxiety and learning and memory impairments seen in HD. P42T treatment presents no effect on Wt mice (Supplementary Material, Fig. S4 ), but is acting on R6/2 mouse model of HD. Both pre-symptomatic and post-symptomatic treatments of R6/2 mice with P42T reduced the anxiety observed in R6/2 mice. Moreover, in the recognition memory test, untreated R6/2 mice showed a clear recognition deficit in novel objet recognition while R6/2 mice treated with P42T preferentially explored the novel object, whatever the treatment (pre-or postsymptomatic), as observed for Wt mice. These data showed that P42T is able to modulate anxiety level and learning impairments detected in R6/2 mice. Moreover, the peptide was effective on these phenotypes whenever started the treatment. These observations confirmed that P42T is able to act at any stage of the disease, by stimulating the BDNF-TrkB signalling pathway.
Pathological changes induced in HD are often accompanied with reduced plasticity of the synapses, measured by LTP deficit observed in hippocampal slices of HD mice (33, 35) , as confirmed here. BDNF is an important modulator of LTP (44), and is required for LTP in the striatum (45) . In HD, LTP is impaired at cortico-striatal synapses (43), but is rescued by BDNF (33), therefore delaying neuronal dysfunction and improving pathology. We identified that, as for BDNF, P42T is able to increase LTP in the CA1 hippocampal neurons, which can be correlated to an activation of the BDNF signalling. P42T is also activating [Ca 2þ ]i changes mediated in cultured hippocampal neurons, highlighting a role of P42T in synaptic plasticity and neuronal activity, also in Wt cells.
Globally, we found that P42T first targets the TrkB levels of expression both in Wt (Supplementary Material, Fig. S3) , and R6/2 mice (Fig. 2) . Local and specific regulation of TrkB was proposed to serve as a 'coincidence detector' for spatio-temporal control of BDNF signal (17, 46) . We show in this report that P42T modulates this coincidence detection insured by BDNF/TrkB balance, which plays important role in cortico-striatal projections for neuronal plasticity and activity, as well as learning and memory procedure.
One still opened question is how P42T is able to trigger the activation of TrkB in the striatum. Cortical neurons were shown to play a critical role in the progression of the disease. In particular cortical defects induce changes in postsynaptic trafficking and signalling of TrkB vesicular dynamics in the striatum (47) . Neuronal activity is related to trkB transcription, transport and translation (17) . P42T is potentially acting upstream by enhancing neuronal activity (Fig. 7) , and activating trkB mRNA in the cortex (Fig. 2B ). P42 peptide was also shown to rescue the vesicular transport defects in HD models (25) and, is enhancing TrkB protein in the striatum, as shown here. Hence P42 could potentially enhance trkB mRNA vesicular trafficking along the axons and to the dendrites for a local translation in the striatum. Further studies will be required to identify the exact mechanisms involved regarding the action of P42 on BDNF-TrkB signalling.
As previously shown, we confirmed that the pro-BDNF protein form was detectable in the cortex, whereas mature BDNF was the main represented form in the striatum. Only this mature forms bind to TrkB receptor (48) . Most findings point to a postsynaptic action of BDNF through local activation of TrkB. Our observations support that P42T locally enhances TrkB in the striatum, and induces a postsynaptic response. Indeed even if not conclusive, the unchanged PPR that we observe after acute infusion with P42TAT peptide indicates that the action may rather be postsynaptic, and likely on TrkB receptor.
In HD, multiple lines of evidence suggest that restoring cortical expression, axonal transport, release of BDNF and local activation of TrkB in the striatum promotes neuronal survival and improves behavioural phenotypes in HD animal models (49) . The therapeutic potential of BDNF-TrkB signalling activation in the striatum has been indeed already described (50) (51) (52) . P42T impacts the levels of expression of both bdnf and its receptor trkB, but also ameliorates motor and cognitive functional impairments detected in HD. Direct treatments with BDNF have not been possible, in part because BDNF was unable to directly cross the blood-brain barrier (53) , and also because other factors may be crucial, such as the spatio-temporal balance in the level of expression of BDNF and its receptor TrkB (16, 47) . As shown in this report, the use of P42T may overcome this problem.
Our results show that in addition to the action of P42 peptide on the aggregation process at the early stages of the disease (25, 26) , P42T is also acting on BDNF-TrkB signalling, which improves plasticity and activity of the neurons at the different steps of the disease, during the pre-and the post-symptomatic phases.
Our data show that P42T might ameliorate R6/2 behaviours through BDNF signalling in pre-and post-symptomatic phases of the disease. Therefore, P42T might help not only to prevent but also to treat HD, by acting at different levels of the disease. Also P42 peptide received an orphan drug designation (EMA/ COMP/275974/2015), making P42 peptide a particularly valuable compound to be further examined for its application in HD.
Materials and Methods

Peptide synthesis and formulation
To ensure P42 diffusion, we designed a fusion peptide where P42 (a 23aa peptide) was conjugated to the 11aa TAT Cell Penetrating Peptide (CPP ¼ YGRKKRRQRRR). The peptide P42TAT (AASSGVSTPGSAGHDIITEQPRS-GG-YGRKKRRQRRR) was synthetized and purified by GenScript company. The fusion peptide P42TAT (GenScript, purity >95%) was then diluted in water and this solution was mixed with a lipid mixture (Aonys V R technology, Medesis Pharma, Baillargues) composed of selfassembled specific polar lipids, surfactant and co-surfactants lecithin and ethanol (final water content 12%). After a few seconds of vortexing a (reverse) water-in-oil microemulsion was formed. These microemulsions meet the criteria of a Newtonian fluid (limpid and isotropic liquid) (54) (55) (56) . Aonys 
R6/2 transgenic mice and P42T treatment
Procedures for the care and treatment of animals were carried out in Cecema University animal care, in accordance with directives of the French Ministry of Agriculture (agreement number: D34-172-13).
R6/2 mouse model, based on the expression of the polyQ expanded human exon1 is a well-characterized model showing early and strong symptoms and leading to a premature death at 3 months of age. Initially, heterozygous R6/2 males were obtained from Jackson Laboratory (stock 006494), and crossed with C57BL/6-CBA females. Mice were genotyped by PCR using tail-tip DNA (Supplementary Material, Fig. S1 ), with the following primers: forward-5 0 -CGGCTGAGGCAGCAGCGGCTGT-3 0 ; re-
Females issued from crossings were treated from week 2 to week 12 (for pre-symptomatic treatment), whereas males issued from crossings were treated from week 7 (for postsymptomatic treatment) to week 12. At week 13, mice were sacrificed and brain structures dissected and frozen. The cohorts were divided into several groups comprising Wt and R6/2 mice, treated with empty Aonys V R microemulsion (NT) or with P42TAT-Aonys V R microemulsions, as indicated. Administrations were performed 5 days a week, at the same time of the day. Treatments, either with empty or P42TAT-containing microemulsions (P42T treatment) (1 ml/kg, and peptide dosing 1200 lg/kg) were administrated via 2 injections through buccal and rectal mucosa deposits.
RT-qPCR
Mice dissected brain areas were frozen and homogenized in Trizol REAGENT (Ambion), followed by RNA extraction as Fig. S2 ). 
Western blots
Analysis of brain sections
Behavioural tests of mice
Motor performance was assessed using an accelerating rotarod (Stoelting, Ugo Basile, Biological Research apparatus, Varese, Italy), every week, starting at week 4. On the first day, the mice were trained with a trial at an accelerating velocity from 4.5 to 40 rpm. Subsequently, two trials were performed during two consecutive days. In each trial, mice were placed onto the rotarod at a constant speed of 4.5 rpm for 5 s, which then accelerated at a constant rate up until 40 rpm, for a maximum of 5 min. The daily trial was composed of two sessions of 5 min separated by 5-20 min. The latency to fall from the rotarod was recorded every day for each mouse, and the average of the two last trials was used for statistical analysis.
Light-dark exploration box test
Anxiety was assessed in a light/dark exploration box. The apparatus consisted of two PVC compartments, one with white floor and walls (30 cm Â 25 cm Â 25 cm high), the second one with black walls and roof. A guillotine door separated the two compartments. The clear compartment was brightly illuminated. Each mouse (11 weeks old) was placed in the clear compartment and exploratory activity was videotaped for 10 min. The total time spent and the number of entries into the dark compartment were recorded and analysed using the Videotrack V R software (Viewpoint, Lissieu, France) (57).
Novel object recognition test
Mice at 9 and 11 weeks of age were used for the novel object recognition test. The testing apparatus is an open field (50 cm Â 50 cm Â 50 cm high). The test consists of three sessions. Session 1 (habituation): mice were allowed to freely explore the open-field during 10 min. Session 2 (training): two identical objects were placed in the open-field and mice were allowed to explore them for 10 min. Session 3 (test): 1 h after training, one of the objects was substituted for a novel one (new) while the other remained unchanged (familiar), and mice explored the objects for 10 min. During each session, animal's movements were recorded using the Videotrack V R and Nosetrack V R softwares (Viewpoint). During sessions 2 and 3 the number of nose contacts with the objects were measured and results were expressed as distance travelled (in cm), % of time spent in areas, and preferential recognition index, calculated as the ratio of number of contacts with the object in position 2 over the total number of contacts with the two objects, expressed as percentage (58) . Note that R6/2 mice present memory deficits only at week 11.
Hippocampal neuron-enriched cultures
Primary neuronal cultures were established from 18-day-old embryonic rat hippocampi, as described previously (59,60) with minor modifications. Sprague-Dawley rats were from Janvier (France). After pre-incubation with VerseneTM, hippocampal cells were mechanically dissociated and plated at a density of 2 Á 10 6 cells/dish in eight-well dishes containing glass coverslips.
Culture dishes and coverslips had been previously coated with poly-L-lysine (15 mg/ml) and then with DMEM/HAM F12 containing 10% foetal calf serum. Cells were grown in a defined medium containing DMEM/HAM F12, supplemented with glucose, 33 mM; glutamine, 2 mM; penicillin, 100 U/ml; streptomycin, 100 mg/ml; sodium bicarbonate, 13 mM; transferrin, 50 mg/ml; insulin, 0.5 mg/ml; b-estradiol, 1 pM; triiodothyronine, 3 nM; progesterone, 20 nM; sodium selenite, 46 nM; and putrescine, 100 mM. All experiments were performed on cell cultures grown for at least 10 days in vitro (DIV).
Electrophysiology
Experiments were carried out on brain slices (300 mm thickness) obtained from 8 Slices were then cut with a Vibratome (VT1000S; Leica, France) and maintained at RT for at least 1 h in the same buffer supplemented with 1 mM CaCl 2 . This supplemented buffer-also named extracellular medium-was used for further recordings. Electrophysiological recordings of synaptic transmission were performed on the CA1 area of hippocampal region with either multi-electrode arrays (MEAs) (61) or conventional glass electrode recordings (62) . For MEA recordings, slices were transferred to a MEA (MEA60; Multi Channel Systems, Reutlingen, Germany) continually superfused with the extracellular medium described above (flow rate 2 ml/min). When required, drugs were directly applied in this superfusion. MEAs comprised 60 extracellular electrodes. The inter-electrode distance was 200 mm. Each individual electrode from the array could be used either as a recording or as a stimulatory electrode. A nylon mesh was positioned above the slice to obtain a satisfactory electrical contact between the surface of the slice and the electrode array. Afferent stimulation was achieved with an external stimulator (STG-1004; Multi Channel Systems) by applying biphasic current pulses to one electrode of the array located in the Schaffer Collateral pathway of the hippocampus. Stimulation intensity (60-300 mA) and duration (70-200 ms) were adapted to avoid multiphasic responses due to an excessive stimulation. Field excitatory postsynaptic potentials (fEPSPs) could then be recorded in the CA1 area by electrodes of the array at the same time. Signals were further recorded and analysed (MC Rack; Multi Channel Systems). For glass electrode-based recordings, hippocampal slices were transferred to a submerged-style recording chamber positioned under an upright microscope (DMF, Leica) and superfused with the extracellular medium (flow rate, 2 ml/min). Field EPSPs were recorded in the dendritic field of CA1 hippocampal neurons with glass microelectrodes (4-5 MX resistance) filled with extracellular medium as described above. Field EPSPs were evoked by stimulating the Schaffer collateral-commissural pathway using a bipolar electrode with currents pulses (intensity: 200 mA; duration: 200 ms). Electrophysiological signals were amplified (Axopatch 200B, Axon Instruments) and digitized (Digidata 1200A, Axon Instruments). Field EPSPs were further recorded and analysed with Dr John Dempster's software WinWCP (University of Strathclyde). For recording methods, baseline synaptic signals were evoked using a 0.066 Hz frequency. The stimulus intensity for baseline response was adapted to give around 50% of the maximal response. Slices displaying epileptic-like activity were discarded. Paired-pulse facilitation was measured after applying consecutive pulses with 50 ms intervals (63) . LTP was induced applying a single train of stimuli at 100 Hz for 1 s. The magnitude of the effects on synaptic transmission was determined by measuring fEPSP amplitudes. Data are presented as means 6 S.E.M. on graphs plotting pooled data. Each individual (n) corresponds to an experiment performed on a slice from an individual animal. Experiments were carried out at room temperature.
Measurements of cytosolic-free Ca 2þ concentration
Intracellular calcium concentration ([Ca 2þ ] i ) was measured with the fluorescent indicator fura-2 (64) . For this purpose, hippocampal cells grown on square (10 Â 10 mm) glass coverslips were loaded with fura-2 by a 30 min incubation at 37 C with 2 mM fura-2-AM and 0.02% Pluronic in 'Krebs' extracellular solution (defined above). [Ca 2þ ]i was monitored by videomicroscopy. After rinsing, the glass coverslip was transferred to the recording chamber mounted on an inverted microscope (Leica, DMIRB). Fura-2 emission was obtained by exciting alternatively at 340 and 380 nm with a rotating filter wheel (Sutter Instruments) and by monitoring fluorescent emissions (F340 and F380) at 510 nm. The ratio of emissions at 510 nm (F340/ F380) was recorded every 2 s. Fluorescent signals were collected with a CCD camera (Hamamatsu Photonics), digitalized, and analysed with image analysis software (Acquacosmos; Hamamatsu). Throughout recordings, coverslips were continually superfused (flow rate: 1 ml/min) with the extracellular solution, except when peptides, including P42TAT, were tested. For this, flow was stopped and peptides or vehicle solutions directly added to the recording bath for 25 min. This paradigm was used because of the low amount of peptide available. When required, drugs were applied with a gravity-fed system. On the graphs, data are presented as fura-2 fluorescence ratios F340/F380 obtained in individual cells. Ratios have been normalized to their respective baseline value measured prior to any treatment. Data are expressed as normalized ratio of emissions or F340/ F380. The n values represent the entire population of cells recorded from at least three different cultures.
Statistics
Data are presented as mean 6 S.E.M. Statistical analyses were performed using t-test or nonparametric Mann-Whitney test, when two conditions were compared, and with Wilcoxon matched pairs test when required. One-way or two-way ANOVA (as indicated) or non-parametric Kruskal-Wallis ANOVA were also used when more than two conditions were compared (H value). A P-value of less than 0.05 was considered statistically significant, but P < 0.10, was noted as suggestive of notable trend. Statistical levels were indicated in the text and figures as: *P < 0.05, **P < 0.01, ***P < 0.001. All statistical calculations were performed using the Prism software (GraphPad Software, La Jolla, CA, USA).
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